X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES FRESENIUS KABI ONCO. DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 38.4 22.1 173.3% View Chart
P/BV x 6.2 3.1 199.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DIVIS LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,142176 648.8%   
Low Rs53379 679.1%   
Sales per share (Unadj.) Rs146.637.7 389.0%  
Earnings per share (Unadj.) Rs33.05.1 648.6%  
Cash flow per share (Unadj.) Rs38.46.7 571.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.842.5 523.8%  
Shares outstanding (eoy) m265.47158.23 167.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.73.4 169.2%   
Avg P/E ratio x25.325.0 101.5%  
P/CF ratio (eoy) x21.818.9 115.2%  
Price / Book Value ratio x3.83.0 125.6%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,31820,135 1,104.1%   
No. of employees `00010.81.2 934.2%   
Total wages/salary Rs m4,561703 648.5%   
Avg. sales/employee Rs Th3,616.05,176.2 69.9%   
Avg. wages/employee Rs Th423.8610.4 69.4%   
Avg. net profit/employee Rs Th814.9699.6 116.5%   
INCOME DATA
Net Sales Rs m38,9155,963 652.6%  
Other income Rs m1,13418 6,302.2%   
Total revenues Rs m40,0495,981 669.6%   
Gross profit Rs m12,6171,430 882.3%  
Depreciation Rs m1,425258 552.5%   
Interest Rs m13-26 -51.2%   
Profit before tax Rs m12,3131,216 1,012.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m3,543342 1,035.4%   
Profit after tax Rs m8,770806 1,088.2%  
Gross profit margin %32.424.0 135.2%  
Effective tax rate %28.828.1 102.3%   
Net profit margin %22.513.5 166.8%  
BALANCE SHEET DATA
Current assets Rs m45,3515,102 889.0%   
Current liabilities Rs m6,5072,385 272.8%   
Net working cap to sales %99.845.6 219.1%  
Current ratio x7.02.1 325.9%  
Inventory Days Days127150 84.4%  
Debtors Days Days95113 84.0%  
Net fixed assets Rs m21,1605,148 411.0%   
Share capital Rs m531158 335.6%   
"Free" reserves Rs m58,6256,556 894.3%   
Net worth Rs m59,1566,732 878.8%   
Long term debt Rs m0952 0.0%   
Total assets Rs m67,83210,388 653.0%  
Interest coverage x926.8-45.8 -2,024.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 99.9%   
Return on assets %12.97.5 172.5%  
Return on equity %14.812.0 123.8%  
Return on capital %20.814.6 142.7%  
Exports to sales %074.5 0.0%   
Imports to sales %21.824.8 88.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs m8,4851,477 574.3%   
Fx inflow Rs m32,3595,298 610.8%   
Fx outflow Rs m9,0421,772 510.2%   
Net fx Rs m23,3173,525 661.4%   
CASH FLOW
From Operations Rs m7,7591,274 608.9%  
From Investments Rs m-4,783-1,204 397.2%  
From Financial Activity Rs m-3,142-196 1,602.0%  
Net Cashflow Rs m-166-126 131.4%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.8 0.3 3,933.3%  
FIIs % 19.0 9.6 197.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 9.1 189.0%  
Shareholders   31,796 42,599 74.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS